Kisqali
Olema Secures $250 Million Funding for Pivotal Breast Cancer Trial Featuring Novartis’ Kisqali
Olema, Breast Cancer, Novartis, Kisqali, Pivotal Trial, Funding
Novartis’ Kisqali Secures Broad FDA Approval for Adjuvant Treatment of Early Breast Cancer
Kisqali, Novartis, FDA Approval, Early Breast Cancer, Adjuvant Treatment, HR+/HER2- Breast Cancer, CDK4/6 Inhibitors